undamentalytics Newsletter
Sign in

Insulet Corporation key statistics and ratios

In fiscal 2025, Insulet Corporation had return on equity of 18.1% and a net margin of 9.1%. Each ratio below is calculated from the figures on its income statement, balance sheet and cash flow pages.

Financial ratios

US$ thousands unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2009Dec 20092010Dec 20102011Dec 20112012Dec 20122013Dec 20132014Dec 20142015Dec 20152016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Net margin−109.6%−63.1%−30.1%−24.5%−18.2%−22.3%−27.9%−7.9%−5.8%0.6%1.6%0.8%1.5%0.4%12.2%20.2%9.1%12.3%
Return on equity−116.9%−95.5%−61.5%−81.7%−53.3%−49.4%−124.7%−59.5%−22.2%1.7%8.1%2.0%2.9%0.9%34.1%43.0%18.1%25.6%
Return on assets—−39.1%−24.3%−24.7%−18.5%−17.6%−25.7%−7.9%−4.1%0.4%1.1%0.5%0.9%0.2%8.5%14.7%7.9%11.8%
Effective tax rate—————————36.5%20.0%29.9%18.0%53.1%3.9%−39.3%27.2%24.1%
R&D as % of revenue20.0%17.1%14.4%11.5%8.8%12.1%16.4%15.2%16.3%16.8%17.9%16.2%14.6%13.8%12.1%10.6%11.1%11.3%
SG&A as % of revenue—————————44.0%40.4%42.5%42.4%45.0%43.3%44.3%43.0%42.9%

Returns use average equity or assets over the year. Return on equity is left blank when equity is negative or so small that the ratio says nothing (above ±200%); interest cover is left blank above 200 times. Price-based ratios such as P/E are on the valuation page.

Financial health

5 of 7 checks passed · June 30, 2026
What it owns · $3.2bn
Short-term assets $1.8bnLonger-term assets $1.3bn
What it owes, and who funded it · $3.2bn
Short-term liabilities $744mLonger-term liabilities $999mShareholders' equity $1.4bn
  • Short-term assets cover short-term liabilities $1.8bn of assets due within a year against $744m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $1.8bn short-term assets against $999m of longer-dated liabilities.
  • More cash than debt $535m of cash against $948m of debt.
  • Debt below 40% of shareholders' equity Debt is 67% of equity.
  • Debt burden no higher than five years ago Debt to equity moved from 224% to 67% over five years.
  • A year's operating cash flow covers at least 20% of debt $511m of operating cash flow against $948m of debt.
  • Operating profit covers interest at least five times over Operating income of $516m against $59m of interest.

From Insulet Corporation's latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Moat

36 /100

Weak moat

How hard Insulet's competitive advantage looks for rivals to wear away, judged from 10 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

  • Returns on capital 0 / 20

    Net income has been a median 1.7% of total assets over 10 years.

  • Pricing power 18 / 20

    Gross margin has been a median 66.7%, moving by 3.9 percentage points (standard deviation) across 10 years.

  • Durability 1 / 20

    Operating margin has been a median 7.0%; its worst year was -2.5%.

  • Cash conversion 4 / 20

    Free cash flow was positive in 4 of 10 years, at a median -6.0% of revenue.

  • Discipline 13 / 20

    The diluted share count rose 5.3% over five years; stock-based pay has been a median 3.3% of revenue.

AI disruption exposure: Low. In this industry, the business rests on physical assets, regulated networks or products AI itself depends on.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Compare with peers

Head to head: GMED vs PODDPODD vs RVTYPODD vs QDEL

More: Health Care Equipment stocks compared, Health Care sector, rankings of US companies

Figures from Insulet Corporation's SEC filings (10-K and 10-Q), retrieved October 20, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Insulet Corporation.